Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
GTGR~~FLOAT 440,264 will run like tornado here,keep looking
GTGR~~love the bid support,something in the pipeline,believe you or not dollars here with ne next update,but will be late for some folks
GTGR: CORRECT TA has SS as of 01/23/2018
FLOAT 440,264
O/S 1,625,888
Restricted-1,185,624
Pacific Stock Transfer
800-785-7782
GTGR~~Contact us
Golden Technology Group LTD.
Tel: +86 755 2320 9159
Fax: +86 755 3385 6092
Office Address:
Room711-712,7F,Block A,Building 1,Futong Ruishangju,Hangcheng Avenue,Xixiang Street,Bao'an District,Shenzhen City,Guangdong Province,China518126
Factory Address:
Baozhiwei Technology Park,No.51,Guangtian Road,Luotian Community,Songgang Town,Bao'an District,Shenzhen City,Guangdong Province,China518105
Overseas Deppartment:
Name: Cherry Zhang
E-mail: cherry@golden-tech.cn
Service & QC Department:
Name: Mr.Li
E-mail: assistant1@golden-tech.cn
GTGR~~HUGE HERE~~With 11 Years of ODM and OEM Experiences
Golden Tech has 11 years of ODM and OEM experience in manufacturing computer peripherals, consumer electronic products in technology. We have a 100% self-owned printing factory for product packaging decoration. We have passed the WCA and Walt Disney audits, and obtained GMI certification.
Professional Bluetooth Business Service
We specialize in producing Bluetooth speakers, patented lenses for smart phones, patented selfie sticks, keyboards, mice and power adapters including type-C adapters.
Our products are widely recognized and trusted by global users mainly from Asia, Europe, the US and Africa, and can meet developing economic social system's demand. "Quality products, high efficiency, innovative ideal and best service" is our principle for serving our clients.
Benefit from Our Advantages
Our product quality is highly ensured by our experienced specialists in every department from R&D, QC to QA. We own the most advanced equipment from Japan (Komori7+1UV and 5C printing machine). Armed with fashion and unique design and high technology, our position as one of the leaders of ODM and OEM services has been well-known in global market.
In addition, we have our self-designed brands MGSS, G-TECH and GOBOMAN, and obtained nine patents already. Throughout the years, we have successfully cooperated with global famous brands such as Walmart, Best Buy, Target, Walt Disney, Sanrio, Walgreen and more.
Contact Us Today
We are willing to establish long term stable business relationships with more customers from all over the world. We welcome you to choose our stylish products in the global business chain. Contact us today to begin sourcing.
We are warmly looking forward to your Hong Kong visits for our Tech-booth at AsiaWorld-Expo on October 11 to 14, 2017 on Global Sources Electronics Show. See you there.
ENTITY name the same Golden Tech Group, Ltd. on YAHOO
#116 Huanshi South Street
Qinghutou Tangxia Town
Dongguan 523726
China
86 769 8262 1412
http://www.golden-tech.cn
https://finance.yahoo.com/quote/GTGR/profile?p=GTGR
same on fillings
GOLDEN TECH GROUP, LTD same on fillings
http://nvsos.gov/sosentitysearch/corpActions.aspx?lx8nvq=A4N6G0U3DOJv6tv6BXXG8w%253d%253d&CorpName=GOLDEN+TECH+GROUP%2c+LTD
GTGR~~I'm not sure if this website is a new GOLDEN TECH GROUP, LTD company website ,but if? willbe HUGEEEEEEEEEEEEEEE money here to make http://www.golden-tech.cn/
GTGR~~Valuation
Price to Book Ratio
7.14
Price to Cash Flow Ratio
5.61
Total Debt to Enterprise Value
0.01
https://www.marketwatch.com/investing/stock/gtgr/profile
GTGR~~tomorrow fan here,chasing time
GTGR: CORRECT TA has SS as of 01/22/2018
FLOAT 440,264
O/S 1,625,888
Restricted-1,185,624
Pacific Stock Transfer
800-785-7782
GTGR~~ROBERT CHIN NEW Director -President-Secretary-Treasurer
http://nvsos.gov/sosentitysearch/CorpDetails.aspx?lx8nvq=A4N6G0U3DOJv6tv6BXXG8w%253d%253d
GTGR~~NEW NAME GOLDEN TECH GROUP, LTD.
GTGR~~L2 .25,.30,$1.10,$2.25 Wow
GTGR~~~NEW CEO~~~Director - ROBERT CHIN
Address 1: 2964 LINCOLN HIGHWAY Address 2:
City: SADSBURYVILLE State: PA
Zip Code: 19369 Country:
Status: Active
http://nvsos.gov/sosentitysearch/CorpDetails.aspx?lx8nvq=A4N6G0U3DOJv6tv6BXXG8w%253d%253d
Revival filed on NVSOS. New officer Robert Chin http://nvsos.gov/sosentitysearch/corpActions.aspx?lx8nvq=A4N6G0U3DOJv6tv6BXXG8w%253d%253d&CorpName=GOLDEN+TECH+GROUP%2c+LTD.
Been 7yrs since last post volume nonexistant:
Contact Info
Tian Yuan
5th Floor, Xiangyi Hotel
Baofeng Er Lu, Hankou
Wuhan
China
Update Company Info
Business Description
Financial Reporting/Disclosure
Reporting Status Alternative Reporting Standard
Deregistered a/o Jun 15, 2006
Audited Financials Not Available
Latest Report Not Available
Regulatory Agency Not Available
CIK 0001009919
Fiscal Year End 1/31
OTC Market Tier OTC Pink No Information
Profile Data
SIC - Industry Classification 2834 - Pharmaceutical preparations
Incorporated In: NV, USA
Year of Inc. 1998
Employees Not Available
Company Officers
Reid H.Y. Li President, Acting CEO, Secretary
Company Directors
Not Available
Company Notes
Formerly=Amersin Life Sciences Corp. until 5-07
Formerly=Hubei Pharmaceutical Group, Ltd. until 1-05
Formerly=Pan Asia Communications Corp. until 4-03
Formerly=Explore Technologies, Inc. until 6-02
Service Providers
Auditor/Accountant
Not Available
Legal Counsel
Not Available
Investor Relations Firm
Not Available
GTGR Security Details
Share Structure
Market Value1 Not Available
Shares Outstanding Not Available
Float Not Available
Authorized Shares Not Available
Par Value 0.001
Shareholders
Shareholders of Record Not Available
Security Notes
Capital Change=shs decreased by 1 for 10 split. Pay date=09/25/2001.
Capital Change=shs decreased by 1 for 10 split. Pay date=4-3-03
Capital Change=shs decreased by 1 for 20 split. Pay date=05/21/2007.
Short Selling Data
Short Interest 0 (-100%)
Aug 15, 2007
Significant Failures to Deliver No
Transfer Agent(s)
Pacific Stock Transfer Co.
On the sidelines for now...This after hours press release (6pm) has me concerned, and this big drop recently made no sense either.We'll see.
http://biz.yahoo.com/pz/050915/86132.html
Amersin Notifies Chinese Joint Venture That it Will Not be Providing Additional Funds
Thursday September 15, 5:56 pm ET
NEW YORK, Sept. 15, 2005 (PRIMEZONE) -- Amersin Life Science Corporation (OTC BB:AMLS.OB - News) Chief Executive Officer, H.Y. (Reid) Li, announced that the company notified the minority partners in its Hubei Tongji Benda Ebei Pharmaceutical Co. Ltd. joint venture in Hubei Province China today, that it did not believe it would be in the best interest of its shareholders to advance additional funds to complete acquisition of its interest or to provide additional working capital. It is anticipated that discussions and negotiations will take place over the next several weeks which may lead to the company holding a minority position in the Joint Venture, selling its interest in the joint venture back to the vendors (a company controlled by the minority partners) or other outcome which is not yet determined. Additional information will be made available once a definitive agreement has been determined.
ADVERTISEMENT
``Safe Harbor'' Statement:
This news release contains certain ``forward-looking'' statements within the meaning of Section 27A of the Securities Act of 1933, as amended, Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995. Actual results may differ materially from the forward-looking statements contained herein. Detailed information about many risk factors are set forth in Amersin's periodic filings with the Securities and Exchange Commission including, but not limited to, those risks and uncertainties listed in the sections entitled ``Cautionary Note Regarding Forward-Looking Statements'' and ``Management's Discussion and Analysis'' in Amersin's most recent Quarterly Report on Form 10-QSB. All documents are available through the SEC's Electronic Data Gathering Analysis and Retrieval system (EDGAR) at http://www.sec.gov or the Amersin web site at http://www.amersin.com. Amersin is under no obligation, and expressly disclaims any obligation, to update or alter its forward-looking statements, whether as a result of new information, future events or otherwise.
The Amersin Life Sciences Corp. logo is available at: http://www.primezone.com/newsroom/prs/?pkgid=1616
Contact:
Amersin Life Sciences Corporation
Corporate Communications:
Howard Milne
604-881-2899, Ext 220
Fax: 604-881-2892
howard@amersin.com
--------------------------------------------------------------------------------
Source: Amersin Life Sciences Corp.
Any word on the progress of the "solids" facility? Construction should be complete if they are on schedule. Also wondering if they converted their short term notes to long term like they expressed the need to do.
HomerRomer
Flu pandemic is possible, official says...
http://www.newsday.com/news/health/ny-liflu304405000aug31,0,2541971.story?coll=ny-health-headlines
BY BRANDON BAIN
STAFF WRITER
August 31, 2005
An official of the state Department of Health raised the possibility yesterday of a worldwide outbreak of the avian flu, citing the shortage of vaccines in recent years and the ability for the virus to mutate and travel globally.
Barbara Wallace, director of communicable disease control for the agency, told health professionals at the Nassau County Bar Association in Mineola that in the event of a pandemic - or widespread outbreak - a flu shot would not be immediately available. Consequently, members of the general population may have to receive more than one anti-viral shot to offset the effects of the virus, she said.
Wallace stopped short of predicting a pandemic. But, given that vaccine supplies are "unpredictable," she urged local health officials to remain vigilant. "We're making sure people are talking," Wallace said. "It's not to scare people, but to get people used to the idea."
To prepare for an outbreak, Wallace said, state officials have increased surveillance of the flu virus and established stockpiles of anti-viral drugs and vaccines.
An influenza pandemic would arise if a new form of the virus were to spread to the overall population and there were no vaccines to prevent it. In the 20th century there were three major pandemics, the last one in 1968 resulting in 34,000 deaths.
"Clearly the transportation for something to move much quicker is there these days," Wallace said, referring to the recent SARS and bird flu epidemics. "Something that took months to move from Asia to the United States could happen overnight."
Last year's vaccine shortage has caused local officials to address the issues sooner.
"We're hopeful that a pandemic would never come here, but I'm concerned about a flu vaccine again this year, because the resources have not been as good as they should be," said Norma Henriksen, acting chairman of the Board of Health for Nassau County.
Lauren Barlow, a public health nurse coordinator in Suffolk County, said health officials should have a better sense of the vaccine supply by September or October. "We expect to have at least as much vaccine as we did last year," she said.
According to a presentation by Barlow, in an estimated worst-case scenario, a flu pandemic could lead to an estimated to 14,916 flu-related hospital admissions a week and 2,609 hospital deaths in New York State. The report excluded New York City.
Some local health officials are also seeking help from the Medical Reserve Corps, an all-volunteer group of health professionals that helped distribute new shipments of the vaccine in Long Island last year.
"Based on the problems we had last year with the flu vaccine shortage, that's certainly something that we are very concerned about and we may need our medical reserve force," said Shelly Schechter of Nassau County's department of public health.
Well, back to about where we were before that little dump fest.All these mid to longer term plays will heat up in the fall IMO.
~Rig
Looking good and I am hearing it will get better.~Rig
Nice timing: I have a bunch but did not add enough.
Thanks Rig. -T
First bird flu deaths in Indonesia...
http://www.cnn.com/2005/HEALTH/conditions/07/20/bird.flu.reut/index.html
Wednesday, July 20, 2005; Posted: 3:48 a.m. EDT (07:48 GMT)
JAKARTA, Indonesia (Reuters) -- Indonesia has confirmed its first deaths from bird flu, saying tests on a father and his two young daughters who died recently showed they had the virus, a minister has said.
"Test results from a Hong Kong laboratory which I received this morning confirmed they were positive for the H5N1 virus," Health Minister Siti Fadillah Supari told reporters on Wednesday.
Asked if the three died from bird flu, Supari said: "Yes."
"It is not yet known how they got infected, but we continue to conduct an investigation on the ground," she said.
"The results show (the virus is) a conventional one, and not a new virus. Therefore, there is no need to worry about human-to-human transmission."
Authorities have taken samples of more than 300 people who had contact with the family on the outskirts of Jakarta.
They also plan to carry out extensive tests on animals within a 20-kilometer (12-mile) radius of the family's house and slaughter those infected.
The bird flu virus, which arrived in Asia in late 2003, has previously killed 40 people in Vietnam, half of them since December, 12 in Thailand and four Cambodians.
Health authorities fear the virus will mutate and become easily passed between humans, causing a global pandemic.
Last month, Indonesia reported its first human case in a poultry worker, but the man did not develop symptoms and is healthy.
Copyright 2005 Reuters. All rights reserved.This material may not be published, broadcast, rewritten, or redistributed.
Rig,
I may be jumping the gun, but it looks like the seller is done for now...
regardless, I am very pleased to be in what looks to me like a defensive place to be....
defensive as in bottomed out, bird-flu risk, decent earnings.
we'll see. I am on the bid at .121
Timing
Timing,
Hencne the name "Timing".lol.
Rig
Rig,
I had planned on buying AMLS in the 17 cent range...
I am not waiting around for the stock to bounce back to mid to high teens to get in. This sudden and surprise crash creates a dream entry price. Whatever the reason for the crash, it is more than likely priced in. The stock is off about 90% in 3 months? I repeat, time to buy!
Timing
Caught it at .08 and sold at .10 for a $500 quickie before
heading to the theme park for my sons 13th birthday.
:)
Timing,
I grabbed a few but still have not been able to find out who did the dumping or what's the reason for todays drop.I dont see anything in filings of 144 etc that gives me a clue.I'm not sure its timing to buy anything right now.lol.
~Rig
Time to buy?
I think so.
Thanks HomerRomer...this is the second undervalued gem that you have brought me to. The first was SRGL....loaded that one....will probably load this one.
Timing
stocks4john,
no Idea.Been watching though.I dont see any filings.
Rig
AMLS is taking a dump today. Any reason why?
TIA
HomerRomer,
Nice that someone has read the filings of this compamy and done some dd... :)Rig
The more I look into this company, the more excited I get.
~They are a anti-viral producer in a world were every government is trying to accumulate a huge stockpile in case of an Avian Flue outbreak.
~They are growing sale and improving margins in a company that is already profitable. (more than $2mm profit in first 8 months)
~They are only 2-3 months away from beginning production in their new "solids" factory which they will immediately begin to introduce their highest margin products. (Two of those products are 36 mm/yr drugs in which they expect to be the only domestic manufacturer which should lead to a nice market share.) "It will also allow us to apply for licenses to produce the two new high profile biotech products used to treat cancer and diabetes which were acquired at the time of the acquisition of our interest in Hubei Benda."
~"Although it is possible we will achieve significant sales levels with some products as they are introduced and perform beyond expectations, projections for the 2005 fiscal year do not include significant revenues from the solids line. Management is confident that an extrapolation of the eight months performance in the previous fiscal year to a full operating year are realistic, resulting in sales revenues of between 9 and 10 million dollars and net operating profits of approximately 3 million dollars"
~They have over 70 products that they can produce, but are just concentrating on those with the highest margins and the least competition at this time. Once they have the new facility established, they will have an endless amount of other products they can introduce and hopefully bundle with their more elite drugs.
~The stock will then almost reach $30 per share before they have quality issues and have to recall their entire line of products and the stock will drop back down to $4 pps. (LOL. Seeing if anyone was paying attention. AMLS was reminding me a little of ABRX when I loaded up around this same $.28 level. AMLS actually seems to have TONS more going for them than when ABRX was at .28.)
Hope they can follow through on their plans. If so, this could be a nice long hold for me.
HomerRomer
quite nice!!! ~Rig
10KSB: AMERSIN LIFE SCIENCES CORP
By Edgar Online - (EDG = 10Q, 10K)
Last Update: 6/2/2005 12:58:49 PM Data provided by
(EDGAR Online via COMTEX) -- Item 6 - Managements Discussion and Analysis or Plan of Operation
This Management Discussion and Analysis focuses on key information drawn from the consolidated financial statements of Amersin Life Sciences Corporation for the year ended January 31st, 2005 and pertains to known risks and uncertainties relating to its businesses. It also includes qualitative information prepared by the management of our operating subsidiary to the extent that it is believed to be useful in developing an understanding the results of operations, the risk inherent in operations, the degree to which we will require supplementary funding to obtain our objectives and other matters we believe may be of interest to our shareholders or useful to them in assessing the risks associated with investing in our common stock. It should not be considered all-inclusive as it excludes changes that may occur in general economic, political, and environmental conditions as well as other matters that may, subsequent to the date of this report, become relevant or that did not appear to be relevant at the time of this report. The discussion regarding the financial condition and results of operations should be read in conjunction with the consolidated financial statements and notes to the consolidated financial statements of Amersin Life Sciences Corporation set forth in Item 7 of this report. The reader's attention is also drawn to the cautionary note regarding forward looking statements appearing as page 4 of this report.
Amersin Life Sciences Corporation's business plan is to build an organization involved in all facets of the pharmaceutical life sciences in China through acquisition and vertical integration of controlling interests in operating subsidiaries located in China. To date we have acquired an interest in two dosage form pharmaceutical manufacturing companies. In the fiscal year ended January 31st, 2005 we sold our interest in our first acquisition. Our revenues and reported profitability are all generated by the remaining company, Hubei Tongji Benda Ebei Pharmaceutical Co. Ltd. (Hubei Benda) in which we have purchased a 60% controlling interest. All references in this discussion to operational plans or historical achievements are made with respect to our interest in that operation unless specifically stated otherwise. There is risk inherent in deriving all of our revenues from a single subsidiary. There is also risk in that the laws and regulations regarding acquisitions within the pharmaceutical industry in China may change and significantly impact our ability to grow through acquisitions
Hubei Benda employs 266 full-time employees including 31 Management and Administrative staff, 30 Technologists and Research staff, 23 Sales and Marketing staff and 182 Pharmaceutical production staff. It owns two production facilities: an injection facility used to produce pharmaceuticals in injectable form; and a solids facility used to produce pharmaceuticals in tablet, capsule, oral liquid, powder and other forms. The injection facility was reconstructed and certified to the latest GMP standards in late 2003. Reconstruction of the solids facility commenced in October 2004 and is about 70% complete after which it will also be certified to the latest GMP standards. If construction and certification of the new facility is not completed our business and opportunities for future growth would be materially and adversely affected.
Many licenses are currently commercialized, including: two Heamostatic pharmaceuticals, Tranexamic Acid and Xuejing(R); Nefopan Hydrochloride for pain management; several anti-inflammatories including Shuzheng-B(R) and Riboflavin Sodium Phosphate; Ribavirin, a leading anti-viral; and a range of generic pharmaceuticals. We have a large distribution network covering all major cities in China with agent and marketing offices in Beijing, Tianjing, Wuhan, Guangzhou, and the Guizhou province. Our domestic distribution network continues to expand and there are many opportunities to commercialize additional licenses within the existing channel.
Although we initially purchased a controlling interest in only the dosage forms division we also act as sales agents domestically and internationally for the BendaS&T raw materials and bulk products divisions still owned by the minority partners. There are many opportunities to expand the scope of the joint venture to include some or all of the partners' other interests as improved leverage opportunities and/or funding permit. This expansion is key to our short term plans for growth; however, it will require additional funding we have not yet provided for and without additional funding expansion in this way would not be possible.
In addition to the domestic market, finished and/or bulk products are currently exported to England, Pakistan, India, South Africa and Singapore. BendaS&T has actively pursued development of the export markets throughout the last decade and maintains close cooperative relations with several of the leading multi-nationals. The additional visibility arising from the association with the public company and its investor relations effort regularly generates inquiries from around the world and with them opportunities to develop new relationships and to tender supply of additional products. Although the domestic market provides the largest and most immediate opportunity for rapid growth, international sales and production contracts are a key part of our overall strategy and may provide additional opportunities as we complete the patent and licensing processes for our new biotech products. China is under significant international pressure to revalue its currency. If it does not do so it is possible that some countries will implement restrictive trade policies or tariffs that would have a significantly negative impact on our ability to expand through growth in export sales.
Since acquisition of our controlling interest in Hubei Benda in June 2004, we have focused on restructuring its product lines and streamlining production to place the greatest emphasis on established markets for higher margin pharmaceuticals. This has resulted in modest improvements to gross revenue in key product areas and significant improvements to profitability. Approximately 8% of our net profit is re-invested in Research and Development which has led to the fast-tracking of several new products under development; licensing of two new generic drugs; submissions to China's SFDA for approvals for four new pharmaceuticals; and submission to the Hubei Food and Drug Administration for licensing of eight new pharmaceuticals.
We obtained licensing (National Medicine Authentication Code H20044601) for Tranexamic Acid Injection (0.5g: 5ml), a preferred haemostatic in clinic use.
We obtained licensing (National Medicine Authentication Code H42021048) and began production of Ribavirin Injection (200mg: 2ml), a broad-spectrum anti-viral medicine with an annual domestic market of approximately $73 million dollars. Our minority partner Benda S&T, are the largest producer of bulk Ribavirin in central China which will allow us to compete aggressively for market share if necessary. There are also significant markets for this anti-viral staple throughout South-East Asia.
We obtained approval (Y0405945) from China's SFDA for Vitamin C Injection (1g:
We obtained approval (Y0417118) for Lomefloxacin Aspartate Injection (0.1g: 2ml) and (Y0417119) Lomefloxacin Aspartate Injection (0.2g: 5ml) from China's SFDA.
We obtained approval (Y0416162) from Chinas SFDA for -Asarone an anti-biotic used to treat upper respiratory infection. The annual domestic market is approximately 36 million dollars and currently served through import from other countries. We expect to be the only domestic manufacturer.
We obtained approval (Y0414206) from China's SFDA for Lappaconitine Hydrobromide Tablet a biotech used in the treatment of withdrawal symptoms when treating drug addiction. The annual domestic market is approximately 36 million dollars and currently served through import from other countries. We expect to be the only domestic manufacturer.
We have also submitted and expect approval for eight new products from the Hubei Food and Drug Administration including Asarone in injectable, tablet, granule and liquid forms; the antibiotic Levofloxacin Mesylate and Amino Acid based pharmaceuticals Lysine Hydrochloride Injection (3g: 10ml) and Lysine Hydrochloride Injection (5g: 20ml).
The manufacture and sale of pharmaceutical products in China is heavily regulated by many state, provincial and local authorities. These regulations significantly increase the difficulty and costs involved in obtaining and maintaining regulatory approvals for marketing new and existing products. Our future growth and profitability depend to a large extent on our ability to obtain regulatory approvals. We will not be able to commercialize licenses for pharmaceuticals in sold forms unless and until we complete construction and certification of our new solid-form production facility.
Working closely with local management we have focused attention on marketing initiatives designed to promote brand awareness and broaden distribution. We have developed close cooperative relationships with large wholesalers for generic drugs as well as long-term strategic relationships with a group of key distributors who have large sales networks with strong end-user promotional abilities. These distributors were selected based upon solid core competencies that compliment the new marketing initiatives we are developing in-house and will help to ensure our future domestic market objectives are met.
We view the first eight months of operations to have been a tremendous success.
2004 Fiscal Period Revenue Net Operating Profit Partial Second Quarter(1) $1.85 million $682,000
Third Quarter(2) $2.04 million $636,000 Fourth Quarter(3) $2.50 million $848,000
Amersin's two year strategic plan calls for completion of a vertically integrated industrial chain covering three key tiers of pharmaceutical life sciences including:
·
raw materials and bulk production
·
dosage form production
·
logistics
This will be undertaken in three phases:
In the first phase, management is focused on strengthening and increasing the profitable existing production base by continuing to re-align production to increase return on capital by focusing on higher margin pharmaceuticals with established markets and to use those as leverage to further expand its marketing network for domestic sales. This process is well underway and proof of concept is evident in higher operating margins accompanied by modest sales increases in key product areas leading to significantly improved profitability. Completion of GMP certification of the solids plant will pave the way for commercialization of additional existing licenses as well as several of the new products for which we have received approval in solid form. It will also allow us to apply for licenses to produce the two new high profile biotech products used to treat cancer and diabetes which were acquired at the time of the acquisition of our interest in Hubei Benda.
Our auditors have appropriately included a going concern statement in the Note 1(c) to the financial statements based upon a calculated working capital shortfall of $1,528,845. As calculated, this shortfall includes two items which must addressed. Bank loans totaling $1,573,000 have matured and are now reported as current liabilities. A final payment of $1,205,000 is due with respect to the acquisition of our interest in the joint venture in the coming fiscal year and is accordingly now also included as a current liability. Bank loans are payable in the Chinese currency, are serviced by domestic sales and as such would not be directly affected by a revaluation of the currency. Management does not anticipate difficulty in negotiating new maturity dates for the bank debt. Discussions are ongoing and there is initial agreement; however, with the injection of additional capital would facilitate more favorable terms and longer term restructuring. Successful negotiation of new maturity dates for the bank debt would reduce current liabilities by $1,573,000 and entirely eliminate the working capital deficit as calculated resulting in a small working capital surplus; however, it is important to understand that it would not, in and of itself, provide additional working capital necessary to complete and certify the solids-form production facility or provide working capital with which to increase production and profitability. Our production is currently working capital constrained. Demand exceeds our ability to fund the growth. Additional capital is necessary to overcome this. Under the terms of our acquisition agreement, funds paid to Benda S&T with respect to the acquisition are immediately re-invested in the joint venture as a five-year, non-interest bearing loan. Management is actively considering proposals for funding and anticipates that it will initially raise a small amount of capital, sufficient to meet the company's obligation under the acquisition agreement. This would result in an additional $1,205,000 being restated as long term debt and, in combination with successful renegotiation of maturity dates for the bank debt, would result in a significant working capital surplus. Completion of our investment would not only result in a calculated working capital surplus, it would provide the capital necessary to complete phase one of our two year plan including completion and certification of the solids-form production facility, additional working capital to provide for modest production increases in the injection-form facility and additional working capital to begin ramping up production in the newly certified solid-form production facility. The injection of additional capital would also facilitate restructuring of the bank debt on more favorable terms, potentially also providing increases to short term lines of credit to fund accounts receivable and other demands on capital created by the anticipated increases in production and revenues. It is essential that the company raise additional capital to eliminate the going concern notation and to begin implementation of its near term growth strategy. It is anticipated that the funds required to do this would be raised outside of China. A revaluation of the Chinese currency prior to raising the funds would be expected to have an additional dilutive effect, requiring additional foreign currency to meet the demand.
In the second phase, Amersin plans to purchase a controlling interest in the raw materials and bulk pharmaceutical operations from its minority partner, Benda S&T, thus fully integrating the production chain and making it the largest producer of Ribavirin in China. Ribavirin is a systemic anti-viral sold under the brand names Copegus(R) and Rebetol(R) in the United States, under the brand name Virazol(R) in the United States and Canada and as Tribavirin in the United Kingdom and other parts of the world. It is used to treat severe pneumonia in infants and young children and, in combination with other agents such as Interferon alfa-2B or Peginterferon alfa-2B, to treat a viral liver infection knows as hepatitis C. Work has begun on securing US FDA certification for Ribavirin as a bulk pharmaceutical product. Its position as an established and effective antibacterial in the region is strategically significant in moving forward and securing markets for additional products to treat more recent threats such as SARS or the Avian Flu (H5N1) as they are developed or become available to us for licensing.
In the third phase, Amersin will develop a pharmaceutical logistics center.
Completion of the first phase of our strategic plan is critical to our ongoing success. Although profitable, our resources are underutilized. The injection facility is GMP certified to the latest standards but is working capital constrained and produces pharmaceuticals from a small range of the available licenses. The solids factory is not yet certified to the new standards although work on this is substantially complete. Re-construction is about 70% complete and deposits totaling a little more than 50% of the value of all of the required equipment have been paid. Subject to funding, which we anticipate will result from a combination of debt and equity, the facility is approximately 30 days and $600,000 from completion followed by 30 to 60 days of regulatory processes while it is certified to the latest GMP standards by the State Food and Drug Administration (SFDA). It is constructed entirely in accordance with the plans submitted to and approved by the SFDA. Management have developed a good working relationship with the SFDA, understand the process well following certification of the injection facility and are confident that with May funding in place, construction would be completed by the end of June and the facility would be ready to schedule initial production runs in late August. We have received expressions of interest from several funding sources and anticipate that an offer to finance on commercially acceptable terms is forthcoming. Under the acquisition agreement wherein we acquired our interest in Hubei Benda we owe approximately $1.2 million dollars which will be reinvested in Hubei Benda by the vendor for a period of five years with unspecified repayment terms and carrying no interest.
Phase one funding calls for the injection of 12.3 million RMB (1.5 million dollars) to be used for completion and certification of the solids manufacturing facility and to provide additional working capital to expand production and introduce new products throughout the year. The allocation of funds is detailed in the following table:
In total, $600,000 will be used to complete GMP certification of the solids form manufacturing facility the majority of which will be allocated to completing the purchase price of new manufacturing equipment. An additional $900,000 will be spent and licensing and market development for existing and new products throughout the balance of the year. Completion of this part of our phase one strategic plan will provide Hubei Benda with production facilities certified to the latest GMP standards for production of pharmaceuticals in all common dosage forms including injections, tablets, pills, capsules, granules and oral liquids.
Although we could quickly re-enter the market with a range of generic drugs in solid form to achieve large sales revenues, margins for generic drugs are low.
It should also be noted that we continue to require funding to maintain the parent company. Our expenditures in North America are modest consisting primarily of management fees, professional fees, compliance costs and communications costs. We have historically funded these through the sale of stock and plan to continue to do so as required to allow us to re-invest the profits in the subsidiary for the foreseeable future. We do not have sufficient funds to operate the parent company throughout the current fiscal year without either raising capital through the sale of our stock or drawing on profits generated by the subsidiary.
It is important to note that a pending revaluation of the Chinese Renmimbi (RMB) would have a significant impact on our assets and performance when stated in US dollars. A revaluation of 25% would result in a 33% increase in revenues and profits when stated in US dollars. A 3 million dollar profit would be restated as a 4 million dollar profit. A 30 million dollar revenue projection in subsequent years would be restated as a 40 million dollar projection. It should also be noted that the revaluation of the currency would decrease the purchasing power of the US dollar, requiring more US dollars to achieve the same result and potentially having a dilutive effect. For this reason, management believe that the accretive effects of completing phase one financing in the short term, prior to revaluation of the currency, would largely offset the dilution of any portion of the financing based on equity at this level and would be in the best interest of our shareholders. Fewer US dollars would be required prior to the revaluation which would then be used to complete phase one, generating additional revenues and profitability that would increase further based upon restatement US dollar reported revenues and profitability following the revaluation.
Our investor relations department found in the past that the greatest responses to news about the company's progress came from products with names that are well know in the West or that serve a well understood niche such as birth control, sleep aids or pain management. Since selling our interest in the factory producing those types of products, and in spite of consistent profitability from our most recent acquisition, we have not caught the mind-share of North American investors. We believe this has led to an undervalued stock in comparison to similar micro-cap issues. To date, most of our commercialized licenses have been for products bearing Chinese names or trademarks and used to treat conditions for which there is not a lot of interest. The introduction of products such as Riboflavin, Ribavirin and Erythromycin with their English names may make our material an easier read and attract investors to develop an understanding and . . .
Jun 02, 2005
China takes emergency steps as bird flu found
May 23, 9:52 AM (ET)
By Lindsay Beck
BEIJING (Reuters) - China has sealed off nature reserves and rushed more than 3 million doses of bird flu vaccine to a remote western province after migratory birds were found dead from the H5N1 strain, which can be fatal to humans.
Poultry across far-flung Qinghai province, neighboring Tibet and Xinjiang, had become the "target of a compulsory vaccination campaign," the China Daily newspaper said on Monday.
Scientists had proved that the virus killed scores of geese in Qinghai in early May, media said at the weekend, the first report of H5N1 detected in China since last year.
There had been no reports of the virus spreading to humans or domestic fowl in Qinghai, officials said. The area where the dead geese were found had been sealed off for 10 days.
"So far there has not been any human or any other poultry incident that has been reported and there are a lot of measures that have been taken in terms of prevention (and) in terms of vaccination," Noureddin Mona, China representative for the Food and Agriculture Organization, told Reuters.
The World Health Organization urged surveillance be stepped up.
"In terms of the evolution of the pandemic (threat) if it spreads over a larger area -- and this does seem like a new area -- then it is going to be harder to prise the virus out of the environment," said Dick Thompson, the WHO's spokesman in Geneva.
"This doesn't change the risk assessment but it's still at a high level."
The H5N1 strain has killed 37 Vietnamese, 12 Thais and four Cambodians since it swept across large parts of Asia in late 2003.
Vietnamese health officials said on Monday preliminary tests had shown another person had died of the virus at a hospital in Hanoi last week.
The WHO said last week the spate of human bird flu cases in Vietnam this year suggested the deadly form of the virus may be mutating in ways that are making it more capable of being passed between humans.
SERIOUS RISK
Experts said domestic poultry in China, the world's number two producer after the United States, could also be at risk.
"There is a significant possibility of that, given the fact that wild birds quite often use the same water sources and feeding sources as domestic ducks or domestic geese," said Malik Peiris, a microbiologist at the University of Hong Kong.
"One has to take this risk seriously."
China has been on high alert against bird flu after outbreaks in North Korea and Southeast Asia, which prompted it to tighten quarantine controls at its borders.
But Qinghai is far from either border and domestic media said the birds may have migrated over the Himalayas from India for the mating season.
Mona said affected areas in Qinghai were under quarantine.
"They have already sealed off the affected area and provided all the protective measures," he said.
The areas included an island in Qinghai Lake where more than 178 birds were found dead earlier this month, the official Xinhua news agency said. The island is home to more than 100,000 birds and is a major tourist attraction.
Last year, China successfully controlled outbreaks of bird flu with a combination of vaccinations, culling and surveillance, burning about 145,000 culled birds.
Experts said surveillance was especially important, since the disease had affected several different parts of Asia.
"Clearly it (this outbreak) shows this virus is still causing problems in this region," said Peiris.
~Todays News Release...
Amersin Subsidiary Makes Application to State Food and Drug Administration For New Antiviral Drug License
By Staff
NEW YORK, May 12, 2005 (PRIMEZONE via COMTEX) --
Amersin Life Science Corporation (OTCBB:AMLS) announced today that its subsidiary, Hubei Tongji Benda Ebei Pharmaceutical Co. (Hubei Benda), has applied to the State Food and Drug Administration for a license to produce Yan Hu Ning (Potassium Sodium Dehydroandroan Drographolide Succinate) as a new pharmaceutical in injectable form. It is anticipated that the license will be granted late in the second quarter ending July 31st, 2005.
According to a recent report by the Chinese Southward Medicine Economic Information Center, the global annual incidence of influenza is about 0.6 to 1.2 billion cases. Among those cases, serious influenza represents 3 to 5 million cases resulting in 250,000 to 500,000 deaths. The most prevalent symptom of serious influenza is upper respiratory tract infection. Survival rates are highest among patients receiving immediate medical treatment for serious symptoms.
Yan Hu Ning is prescribed as a fast acting treatment for viral pneumonia and viral infections of the upper respiratory tract and is used extensively throughout China to treat influenza. It is also used to treat chronic bronchitis, gastro-intestinal tract infection and bacillary dysentery.
"The market demand for this new pharmaceutical is 3 billion RMB (US$366 million), said Mr. Charles Wang, President of Hubei Benda, "It is a medicine with enormous domestic market potential. We applied advanced engineering processes to its development and will enjoy a strong competitive position for Yan Hu Ning in the domestic pharmaceuticals market."
About Amersin Life Sciences Corporation:
Amersin's profits are derived from its subsidiary located in Hubei province, the center of pharmaceutical production and research within China and home to very large scale automobile production, abundant natural resources and links to high capacity transportation systems serving the rest of the country. It employs 266 full-time employees and owns two high capacity modern facilities for the production of dosage form pharmaceuticals in injectable form and in solid form including tablets, capsules, granules and oral solutions. Its injection facility is certified to the latest GMP standards and operating profitably. Its solids form facility is scheduled for completion in the second quarter with certification to the latest GMP standards mid third quarter. Following certification it will commercialize additional products from its portfolio of existing licenses, commencing production in the fall, and begin the application process for licenses to produce its two new biotech products used to treat diabetes and certain forms of cancer for release early next year.
Amersin is committed to building investor equity through strategic acquisition and vertical integration of operating subsidiaries and controlling joint venture interests in China to include all facets of pharmaceutical life sciences from raw materials through dosage form production and distribution. It is poised to become one of the leading American corporations to profit from the burgeoning life sciences sector in China. Additional information may be requested via Amersin's web site at http://Amersin.com
"Safe Harbor" Statement:
This news release contains certain "forward-looking" statements within the meaning of Section 27A of the Securities Act of 1933, as amended, Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995. Actual results may differ materially from the forward-looking statements contained herein. Detailed information about many risk factors are set forth in Amersin's periodic filings with the Securities and Exchange Commission including, but not limited to, those risks and uncertainties listed in the sections entitled "Cautionary Note Regarding Forward-Looking Statements" and "Management's Discussion and Analysis" in Amersin's most recent Quarterly Report on Form 10-QSB. All documents are available through the SEC's Electronic Data Gathering Analysis and Retrieval system (EDGAR) at http://www.sec.gov or the Amersin web site at http://www.amersin.com . Amersin is under no obligation, and expressly disclaims any obligation, to update or alter its forward-looking statements, whether as a result of new information, future events or otherwise.
SOURCE: Amersin Life Sciences Corp.
Amersin Life Sciences Corporation
Corporate Communications:
Howard Milne
604-881-2899 Ext 220
604-881-2892 - Fax
howard@amersin.com
--------------------------------------------------------------------------------
(C) 2005 PRIMEZONE, All rights reserved.
News provided by
rig is amls supposed to release their financials this week, wonder what's holding them up, think everybody is waiting for it, as evident by the last two days
Rig:
Let's take our AMLS discussion over here from the CESV board so as to not upset anyone.
Len
koolmc,
selling drying up, the float is only around 4 million.We move back up easy on next piece of strong news IMO.
~Rig
koolmc,
I have no expectations right now with the q, for me if they keep signing contracts, with minimal dilution.I am still very new with this play and look forward to the upcoming filing to get more of a feel for where they are headed and how much more profit we can retain.
The previous prs indicate a good immediate future with regard to sales.
Rig
rigatoni what are you expecting from the upcoming year end and fourth quarter financials?
Some bird flu news...
http://news.telegraph.co.uk/news/main.jhtml?xml=/news/2005/04/16/wbflu16.xml
Bird flu outbreak leads to fears of pandemic
By Sebastien Berger in Hanoi and Roger Highfield, Science Editor
(Filed: 16/04/2005)
The threat of a killer flu pandemic is greater than ever because of the spread of the bird flu virus in south-east Asia, the World Health Organisation said yesterday.
Avian influenza is still spreading, despite countermeasures, and the possibility of a global epidemic that could kill millions is said to be more likely than not.
In its current form, humans can't easily catch the virus
More than 50 people have died from the H5N1 virus in south-east Asia, most of them in Vietnam, where tens of thousands raise poultry in small back-yard farms.
In its current form, the virus is difficult for humans to contract, but if it changes its genetic make-up, it could spread rapidly.
If the virus infects a person who has a human flu virus, the two may shuffle their genes to create a deadly mix.
A new strain could combine the lethal effects of the bird virus with the ability to spread easily among people supplied by the human virus.
The World Health Organisation (WHO) computer models suggest that a pandemic of H5N1 would kill between 2 million and 7.4 million within 12 months in a "best case scenario" based on the "mild" pandemic of 1968.
But if it were similar to the 1918 pandemic, the models estimate a much higher total.
Peter Horby, the WHO medical epidemiologist in Hanoi, said that while the mortality rate from H5N1 infections was falling, the virus appeared to be adapting to human hosts, which was taken to be an indication that transmission between humans would become easier.
"The fact that it's been around for a year and we haven't seen a pandemic is no reason to be complacent," he said.
"I'm more concerned than I was a year ago." He estimated the probability of a pandemic at "more than 50 per cent".
Dr Klaus Stohr, the WHO global influenza programme chief, reported an increase in the number of cluster cases reported recently, with the biggest a family of five cases.
There have been seven cluster cases in Vietnam, all within single families, most recently in the northern province of Haiphong.
No relative has been proved to have passed the disease to another, but Dr Horby said: "The onset dates could be consistent with human to human transmission."
The WHO expects to complete the genetic analysis of virus samples from Cambodia and Vietnam within a few days to see if there has been a significant change in its make-up.
To date, there has been human-to-human transmission but none beyond "one or two links in the chain", following close contact with a terminally ill patient.
"The moment we have the slightest suspicion of a change in the epidemiology, we would react very aggressively," Dr Stohr said.
Based on historical patterns, influenza pandemics can be expected to occur, on average, three to four times each century when new virus sub-types emerge and are readily transmitted from person to person.
In the 20th century, the flu pandemic of 1918-1919, which killed up to 50 million, was followed by pandemics in 1957-1958 and 1968-1969.
The viruses that caused these pandemics are all thought to have derived, at least in part, from avian strains. Most influenza experts agree that the prompt culling of Hong Kong's entire 1.5 million poultry population in 1997 probably averted a pandemic.
Britain is among 12 countries that have ordered stocks of a new drug, oseltamivir (Tamiflu), which is effective against H5N1.
2 March 2005: Government stockpiles bird flu drug amid fear of pandemic
9 December 2004: Chicken nuggets could save world from killer flu
The danger in Vietnam's hen coops
© Copyright of Telegraph Group Limited 2005. Terms & Conditions of reading.
Commercial information. Privacy and Cookie Policy.
Followers
|
5
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
104
|
Created
|
04/22/05
|
Type
|
Free
|
Moderators |
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |